UKMS and NMSG guidelines for the Investigation of newly detected M-proteins and the management of MGUS
These guidelines, written by the UK Myeloma Society (previously known as UK Myeloma Forum) in conjunction with the Nordic Myeloma Study Group provide guidance for the effective clinical investigation of patients with newly detected paraprotein and the practical management of patients with monoclonal gammopathy of undetermined significance (MGUS).
Paraproteins can be indicative of various plasma cell disorders, and their detection necessitates careful assessment to determine the underlying cause and appropriate management strategies. MGUS, characterised by the presence of a monoclonal protein without associated symptoms or evidence of malignancy, requires systematic evaluation to monitor for potential progression to more serious conditions, including multiple myeloma or related lymphoproliferative disorders.
These guidelines aim to standardise the diagnostic process, facilitate early identification of patients at risk, and promote optimal management practices. By addressing both investigation and management, the guidelines seek to improve patient outcomes and enhance the overall quality of care for individuals presenting with paraproteinaemia.
Use Cases
Type
Source
You might also like
IMWG immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
Step into the forefront of myeloma treatment with this latest publication from the International Myeloma Working Group immunotherapy committee.
IMWG GuidelineBSH/UKMS good practice paper on Diagnosis and management of smouldering myeloma
Explore the latest guidelines for Smouldering Myeloma care in the British Society for Haematology Good Practice Paper.
BSH GuidelineNICE guidelines on Spinal metastases and metastatic spinal cord compression [NG234]
This NICE guideline covers recognition, referral, investigation and management of spinal metastases and metastatic spinal cord compression (MSCC).
NICE GuidelineIMWG recommendations on the management of multiple myeloma-related renal impairment
The IMWG outline updates to clinical practice guidance for the management of multiple myeloma-related renal impairment.
IMWG GuidelineIMWG consensus guidelines and recommendations for infection prevention in myeloma
Infection poses a significant risk to patients with multiple myeloma, contributing to high rates of morbidity and mortality. This consensus statement from the International Myeloma Society outlines essential guidelines for infection prevention
IMWG GuidelineBSH/UKMS guidelines on the Diagnosis, investigation, and initial treatment of myeloma
These new guidelines, produced by the British Society for Haematology (BSH) and the UK Myeloma Society (UKMS), provide healthcare professionals with guidance on the anti-myeloma management of patients with newly diagnosed myeloma.
IMWG recommendations for the treatment of multiple myeloma-related bone disease
This guideline, authored by an interdisciplinary panel of experts in myeloma and myeloma bone disease, reviews the current evidence and offers management recommendations for myeloma-related bone disease.
IMWG GuidelineScottish referral guidelines for suspected cancer
The Scottish Referral Guidelines for Suspected Cancer were created to help GPs, the wider primary care team, other clinicians, patients and carers to identify those people who are most likely to have cancer and who therefore require urgent assessment by a specialist.
Other GuidelineNICE guideline on Acute kidney injury: prevention, detection and management [NG148]
This NICE guideline provides recommendations for non-specialists for the identification and referral guidance for children and adults who present with symptoms or risk factors of acute kidney injury.
NICE GuidelineIMWG consensus recommendations on imaging in monoclonal plasma cell disorders
The IMWG present recommendations on imaging both in clinical practice and in the trial setting to help standardise the best imaging methods to use as myeloma patients progress through different disease stages.
IMWG Guideline
